NeOnc Technologies Holdings, Inc. (NTHI) AI Stock Analysis

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company that develops treatments for intracranial malignancies. Headquartered in Calabasas, California, the company has 5 employees and was incorporated in 2005. Its lead product candidates include NEO100, a purified form of preillyl acid in a Phase IIa clinical trial, and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is in Phase I/II clinical trials for oral administration to treat primary brain cancers, such as meningioma, high grade gliomas, and glioblastoma, as well as secondary brain cancers.

Revenue rose from $20,000 in FY2022 to $70,462 in FY2023 and $83,000 in FY2024, before declining 51.8% to $39,990 in FY2025. Over the 3-year period from FY2022 to FY2025, revenue achieved a CAGR of 26.0%. Net losses widened from -$3.0M in FY2022 to -$14.9M in FY2023, -$11.9M in FY2024, and -$62.1M in FY2025, resulting in an FY2025 EPS of -$3.56. Research and development expenses were $3.6M in FY2025 compared to $1.2M in FY2022. For the latest quarter ended June 30, 2026, quarterly revenue growth fell 100.0% year-over-year, with trailing twelve months EPS at -$2.13.

As of June 30, 2026, NeOnc Technologies reported $2.0M in cash and short-term investments, total debt of $328,217, and net cash of $1.6M. Total assets stood at $5.2M, while shareholders' equity was -$18.5M, reflecting negative equity. The company's current ratio was 0.14. Operating cash flow in FY2025 was -$20.4M, and free cash flow was -$20.9M after accounting for capital expenditures of $500,000.

NeOnc Technologies holds a market capitalization of $77.8M and an enterprise value of $91.1M. The median of its US-listed Healthcare peers trades at a trailing P/E of 24.6x, a forward P/E of 17.3x, and an EV/EBITDA of 12.0x, alongside an operating margin of 14.0% compared to NeOnc's trailing operating margin of -104418.9%. Over the past year, NTHI shares dropped 74.2%, while the S&P 500 (SPY) returned 16.8%. The stock traded at $2.70 as of October 16, 2026, which is 53.3% below its 200-day moving average.

Four analysts cover NeOnc Technologies, with 3 Strong Buy ratings and 1 Buy rating. The mean price target is $17.00, representing a 529.6% premium over the last close of $2.70. For the fiscal year ending December 31, 2026, analysts estimate EPS of -$1.30 and revenue of $0. For the next fiscal year, estimates project EPS of -$1.09 and revenue of $0. Over the last 4 quarters, the company recorded 0 EPS beats. The next earnings date is November 13, 2026.

This page is an AI-written research summary of NeOnc Technologies Holdings, Inc. (NTHI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NTHI income statement, NTHI balance sheet, NTHI key metrics, NTHI analyst forecast, NTHI chart. See the NTHI stock overview for the latest quote and news.